BTIG Research Issues Positive Forecast for Haemonetics (NYSE:HAE) Stock Price

Haemonetics (NYSE:HAE) had its target price upped by BTIG Research from $130.00 to $142.00 in a report released on Thursday morning, MarketBeat.com reports. BTIG Research currently has a buy rating on the medical instruments supplier’s stock.

Several other analysts also recently issued reports on HAE. JPMorgan Chase & Co. upped their price objective on shares of Haemonetics from $62.00 to $86.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Wall Street Zen upgraded Haemonetics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Mizuho upped their target price on Haemonetics from $95.00 to $140.00 and gave the company an “outperform” rating in a research note on Friday, October 9th. Weiss Ratings raised Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Finally, Raymond James Financial raised their target price on Haemonetics from $105.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $114.11.

Haemonetics Trading Down 3.3%

NYSE HAE opened at $123.17 on Thursday. The stock has a market cap of $5.60 billion, a price-to-earnings ratio of 25.43, a PEG ratio of 2.55 and a beta of 0.63. The firm’s 50 day moving average price is $111.18 and its two-hundred day moving average price is $79.80. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.91 and a current ratio of 3.08. Haemonetics has a twelve month low of $51.00 and a twelve month high of $132.00.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.06. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%. The business had revenue of $357.76 million for the quarter, compared to the consensus estimate of $345.15 million. During the same quarter in the previous year, the company posted $1.27 earnings per share. Haemonetics’s revenue for the quarter was up 9.4% compared to the same quarter last year. Equities analysts anticipate that Haemonetics will post 5.29 EPS for the current year.

Hedge Funds Weigh In On Haemonetics

A number of hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP boosted its holdings in shares of Haemonetics by 21.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock worth $74,731,000 after acquiring an additional 233,119 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Haemonetics by 1,191.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 453,579 shares of the medical instruments supplier’s stock valued at $47,762,000 after purchasing an additional 418,470 shares in the last quarter. Bank of America Corp DE acquired a new stake in Haemonetics during the 2nd quarter valued at $33,326,000. London Co. of Virginia increased its holdings in Haemonetics by 33.9% during the 1st quarter. London Co. of Virginia now owns 352,807 shares of the medical instruments supplier’s stock valued at $19,884,000 after purchasing an additional 89,242 shares in the last quarter. Finally, William Blair Investment Management LLC bought a new position in Haemonetics in the 2nd quarter valued at $24,906,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Fiscal Q2 adjusted earnings were $1.35 per share, above the $1.29 consensus estimate, while revenue of $357.8 million topped expectations of about $345.2 million and increased 9.4% year over year. Haemonetics Q2 results and outlook
• Positive Sentiment: The company raised its fiscal 2027 revenue and organic-growth outlook, signaling confidence in continued demand. Haemonetics raises FY27 revenue outlook
• Positive Sentiment: BTIG Research raised its price target to $142 from $130 and maintained a Buy rating, adding to the positive analyst signals. BTIG Research ratings
• Neutral Sentiment: The earnings-call coverage highlighted a balance between growth and margins. That tradeoff may have tempered the market’s response to the strong headline results, though the available summary does not detail specific margin pressures. Earnings call highlights growth and margin tradeoffs
• Negative Sentiment: Despite the earnings beat and improved outlook, HAE shares moved lower. The pullback may reflect investor caution around the growth-versus-margin tradeoff or profit-taking after the stock reached a 52-week high; these are possible explanations rather than confirmed causes.

Haemonetics Company Profile

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.